The Pharma Data

OCTOBER 19, 2020

DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease. Please read more here. .

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

Drug Discovery World

JULY 18, 2023

These methods offer safer CAR T-based therapies, laying the foundation for clinical trials and the rapid development of a new generation of CAR T cells for both autologous and allogeneic use. Herpesviridae, Polyomaviridae, and Papillomaviridae), bacteria (e.g., Herpesviridae, Polyomaviridae, and Papillomaviridae), bacteria (e.g.,

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

FEBRUARY 15, 2023

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful.

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

DECEMBER 23, 2020

The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020.

Drugs 52

Drugs Licensing Licensing Vaccination 52

The Pharma Data

OCTOBER 14, 2020

The designation of lanifibranor as a Breakthrough Therapy for the treatment of NASH follows the publication in June 2020 of positive topline results from Inventiva’s NATIVE Phase IIb clinical trial with lanifibranor in NASH patients. The trial plans to evaluate safety, tolerability, cytokine profile and efficacy parameters.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52